feed,title,long_url,short_url
Barron's,Sarepta Stock Is Down 57% This Year. Why the Biotech Could Make a Comeback.,https://www.barrons.com/articles/sarepta-stock-price-duchenne-gene-therapy-51629830690?mod=RTA,https://j.mp/3B5VwOn
